Biomica Ltd., a subsidiary of Evogene Ltd. (EVGN), Thursday announced positive data from its ongoing Phase 1 trial of microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, for the treatment of patients with non-small cell lung cancer or NSCLC, melanoma, or renal cell carcinoma or RCC.
StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Evogene Price Performance EVGN stock opened at $0.72 on Friday. Evogene has a 1-year low of $0.45 and a 1-year high of $1.44. The business has […]
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock. Evogene Stock Up 1.3 % Shares of EVGN stock opened at $0.66 on Friday. Evogene has a 12 month low of $0.45 […]